Search NLS News

Valo Therapeutics received approval from Germany’s PEI (Paul Ehrlich Institute) to extend the tumor types to be treated in the company’s current Phase I trial into two subtypes of sarcoma. “This extension of the study into sarcoma is significant as it broadens the range of patients we can recruit into our PeptiCRAd-1 study. These sub-types […]

Alzinova has reported positive top-line results from its phase 1b clinical trial of the vaccine candidate ALZ-101 in Alzheimer’s disease. “The positive top-line results further strengthen our confidence in that ALZ-101 can become a unique therapeutic vaccine and thus help patients suffering from Alzheimer’s disease and their families to a better life. Alzinova has the […]

The previous founder and CEO of BioLamina has gone back to business development, and with his newly founded company he aims to redefine cell therapy development even further. Newly founded Alder Therapeutics is a preclinical phase stem cell therapy development company and, according to Kristian Tryggvason, co-founder and CEO, it is “the next big thing.” […]

Christmas is around the corner. At least that is what it feels like every year by the time I get around to look into gifts for my family. So, this year I started early and came across a special edition of a board game that 2/3 sons can play with each other without significant bloodshed. […]

Calliditas’ partner Everest Medicines has announced that China’s National Medical Products Administration (NMPA) has approved Nefecon for the treatment of primary immunoglobulin A nephropathy (IgAN) in adults at risk of disease progression. Everest also announced that, in addition to Nefecon’s approval in mainland China and Macau, it expects a decision on New Drug Application (NDA) […]

Thomas Kofoed, co-founder and CEO of Alphalyse, describes the life science environment in Odense and shares his favorite spots. Describe the vibe in Odense for a company like yours! “There is a very close relationship between the university/the university hospital and the industry. A lot of students and development projects are performed between academia and […]

The new Shimadzu Brevis GC-2050 is a more compact version of the popular GC-2030. It further advances the Shimadzu tradition of delivering high-precision gas chromatography analyses – while simultaneously saving valuable laboratory bench space.     A space-saving, compact design Laboratory space is very cost-intensive to set up and maintain, and the number of analyses […]

Xbrane Biopharma is focusing the company’s development portfolio and, consequently, the development of Xtrudane (biosimilar candidate to Keytruda) has been terminated. Furthermore, a cost-savings scheme is being introduced which is expected to result in around SEK 50 million in annual savings when fully implemented, states the company. The development of Xtrudane has been terminated Xbrane’s […]

Novo Nordisk has announced the investment of more than EUR 2.1 billion euros starting in 20231 to expand the existing production site in Chartres, France, for the current and future product portfolio within serious chronic diseases. The investment will significantly increase the capacity of the manufacturing site, adding aseptic production and finished production processes and […]

North Carolina (NC) State University and the Danish Technical University (DTU) have the goal to establish a world-class program in bioprocess R&D and workforce training. NLS asked Jennifer Hemphill, Industry Liaison Officer at the DTU Lifelong Learning Program in Denmark about the initiative. Funded by a USD 27 million grant from the Novo Nordisk Foundation […]